XOSL
BRG
, Last price
Name
Borregaard ASA
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Borregaard ASA engages in the development, production, and marketing of specialized biochemicals and biomaterials in Norway, rest of Europe, Asia, the United States, and internationally. It operates in three segments: BioSolutions, BioMaterials, and Fine Chemicals. The company develops, produces, and sells biopolymers and biovanillin for agrochemicals, batteries, industrial binders, and construction, as well as to flavour and fragrance companies, and food and beverage industry. It also develops, produces, and sells speciality cellulose for use as a raw material in the production of cellulose ethers, cellulose acetate, and other specialty products; and cellulose fibrils for industrial applications. In addition, the company provides fine chemical intermediates for contrast agents; and advanced bioethanol products. Borregaard ASA was incorporated in 2012 and is headquartered in Sarpsborg, Norway.
Related entities
Subsidiaries (2)
BORREGAARD AS
Borregaard Deutschland GmbH
Key people
Jan Anders Oksum
Independent Chairman of the Board · since 2012
President, Chief Executive Officer · since 1999
Per Bjarne Lyngstad
Chief Financial Officer · since 1998
Tuva Barnholt
Senior Vice President - Strategic Sourcing · since 2005
Sveinung Heggen
General Counsel · since 2013
Ole Gunnar Jakobsen
Plant Director of Borregaard's Sarpsborg Site (Norway) · since 2006
Ragnhild Anker Eide
Director, Employee Representative · since 2012
Roy Kare Appelgren
Observer · since 2012
Asmund Dybedahl
Director, Employee Representative · since 2013
Independent Director · since 2018
Independent Director · since 2018
Headquarters & legal address
Hjalmar Wessels vei 6
Sarpsborg, 30 1721
NO
Sarpsborg, 30 1721
NO
Valuation
Title NOK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||